Zevra Therapeutics Mixed Q2 Results: Details
Portfolio Pulse from Erica Kollmann
Zevra Therapeutics (NASDAQ:ZVRA) reported mixed Q2 results with a loss of 48 cents per share, missing analyst estimates by 9.09%, but quarterly sales of $4.449 million beat expectations. Increased R&D expenses were noted, driven by the KP1077 Phase 2 trial. Shares are down 1.18% after-hours.
August 13, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zevra Therapeutics reported a Q2 loss of 48 cents per share, missing estimates by 9.09%, but sales of $4.449 million beat expectations. Increased R&D expenses were driven by the KP1077 Phase 2 trial. Shares are down 1.18% after-hours.
The mixed results, with a significant EPS miss and increased R&D expenses, likely contributed to the after-hours decline in share price. The sales beat provides some positive news, but the overall impact is negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100